Duc DD, de Vries PJ, Nguyen XK, et al. The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects. Am J Trop Med Hyg. 1994;51(6):785-90.
Efferth T, Dunstan H, Sauerbrey A, et al. The anti-malaria artesunate is also active against cancer. Int J Oncol. 2001;18:767-73.
Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med 2007;73(4):299-309.
Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995;91(1):41-6.
Lai H, Singh NP. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett. 2006; 231(1):43-48.
Li Y, Shan F, Wu JM, et al. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett. 2001;11(1):5-8.
Oh S, Kim BJ, Singh NP, et al. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett. 2008; E-pub ahead of print.
Sadava D, Phillips T, Lin C, Kane SE. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. cancer Lett. 2002;179(2):151-6.
Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 2001;70(1):49-56.
Singh NP, Verma KB. Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch oncol 2002;10(4):279-80.
Willoughby Sr JA, Sundar SN, Cheung M, et al. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 promoter and inhibiting CDK4 gene expression. J Biol Chem 2008; E-pub ahead of print.
